Measles outbreak in a Roma community in the Eastern region of Slovakia, May to October 2018

Henrieta Hudečková; Janka Stašková; Ján Mikas; Adriana Mečochová; Edita Staroňová; Alexandra Polčičová; Tibor Baška; Martin Novák; Nora Malinovská; Jana Zibolenová; Viera Švihrová; Elena Nováková; Mária Štefkovičová

doi:10.2478/sjph-2020-0028

.blurhash-client-img { display: none !important; }

Measles outbreak in a Roma community in the Eastern region of Slovakia, May to October 2018

Slovenian Journal of Public Health

Volume 59 (2020): Issue 4 (December 2020)

By: Henrieta Hudečková, Janka Stašková, Ján Mikas, Adriana Mečochová, Edita Staroňová, Alexandra Polčičová, Tibor Baška, Martin Novák, Nora Malinovská, Jana Zibolenová, Viera Švihrová, Elena Nováková and Mária Štefkovičová

Open Access

|Oct 2020

Figures & Tables

Map of the reported measles cases by districts, Slovakia, May 4–October 16, 2018 (n=439).
Source: EPIS SR, © Public Health Authority of the Slovak Republic

Measles incidence rate and measles vaccination coverage according to the cohorts 1999-2016, the Michalovce and Sobrance districts in the Košice region, Slovakia, 1997-2018.

The epidemic curve of the total measles cases, May–October 2018, for the Michalovce and Sobrance districts, Slovakia (n=439).

Table 1

Characteristics of all patients (n=439) and of patients vaccinated with two MCV doses (n=102) in the measles outbreak in Michalovce and Sobrance districts, Slovak Republic 2018.

Characteristic	0	1-4	5-9	10-14	15-19	20-24	25-34	35-44	45-54	TOTAL
Males	33	27	30	35	38	16	19	10	4	212
Females	48	33	42	30	38	13	12	8	3	227
TOTAL (%)	81 (18.5)	60 (13.7)	72 (16.4)	65 (14.8)	76 (17.3)	29 (6.6)	31 (7.1)	18 (4.1)	7 (1.6)	439 (100.0)
Hospitalized	72 (16.4)	51 (11.6)	52 (11.8)	31 (7.1)	47 (10.7)	18 (4.1)	13 (3.0)	2 (0.5)	2 (0.5)	288 (65.6)
Complications	10 (2.3)	8 (1.8)	6 (1.4)	2 (0.5)	8 (1.8)	1 (0.2)	3 (0.7)	0	1 (0.2)	39 (8.9)
	VACCINATION STATUS (%) (n=439)
MCV1
MMR*	0	21 (4.8)	58 (13.2)	15 (3.4)	13 (3.0)	10 (2.3)	6 (1.4)	0	0	123 (28.0)
MM**	0	0	0	0	0	0	1 (0.2)	0	0	1 (0.2)
Mo***	0	0	0	0	0	0	0	2 (0.5)	1 (0.2)	3 (0.7)
All MCV1	0	21 (4.8)	58 (13.2)	15 (3.4)	13 (3.0)	10 (2.3)	7 (1.6)	2 (0.5)	1 (0.2)	127 (28.9)
MCV2
MMR*	0	0	0	37 (8.4)	52 (11.8)	17 (3.9)	10 (2.3)	2 (0.5)	0	118 (26.9)
MM**	0	0	0	0	0	0	0	1 (0.2)	0	1 (0.2)
Mo***	0	0	0	0	0	0	9 (2.1)	7 (1.6)	2 (0.5)	18 (4.1)
All MCV2	0	0	0	37 (8.4)	52 (11.8)	17 (3.9)	19 (4.3)	10 (2.3)	2 (0.5)	137 (31.2)
All vaccinated	0	21 (4.8)	58 (13.2)	52 (11.8)	65 (14.8)	27 (6.2)	26 (5.9)	12 (2.7)	3 (0.7)	264 (60.1)
Unvaccinated	0	23 (5.2)	14 (3.2)	12 (2.7)	5 (1.1)	1 (0.2)	0	0	3 (0.7)	58 (13.2)
Unvaccinated for age	81 (18.5)	16 (3.6)	0	0	0	0	0	0	0	97 (22.1)
All unvaccinated	81 (18.5)	39 (8.9)	14 (3.2)	12 (2.7)	5 (1.1)	1 (0.2)	0	0	3 (0.7)	155 (35.3)
Unknown	0	0	0	1 (0.2)	6 (1.4)	1 (0.2)	5 (1.1)	6 (1.4)	1 (0.2)	20 (4.6)
	Characteristics of patients vaccinated with 2 MCV doses in the measles outbreak in the Michalovce and Sobrance districts (n=102)
Males	0	0	0	13	22	7	6	4	1	53
Females	0	0	0	10	23	5	7	3	1	49
TOTAL (%)	0	0	0	23 (22.5)	45 (44.1)	12 (11.8)	13 (12.8)	7 (6.9)	2 (2.0)	102 (100.0)
	VACCINATION STATUS (%) (n=102)
MCV1
MMR*	0	0	0	0	0	0	0	0	0	0
MM**	0	0	0	0	0	0	0	0	0	0
Mo***	0	0	0	0	0	0	0	0	0	0
All MCV1	0	0	0	0	0	0	0	0	0	0
MCV2
MMR*	0	0	0	23 (22.5)	45 (44.1)	12 (11.8)	13 (12.7)	0	0	93 (91.2)
MM**	0	0	0	0	0	0	0	0	0	0
Mo***	0	0	0	0	0	0	0	7 (6.9)	2 (2.0)	9 (8.8)
All MCV2	0	0	0	23 (22.5)	45 (44.1)	12 (11.8)	13 (12.7)	7 (6.9)	2 (2.0)	102 (100.0)

* TRIMOVAX, PRIORIX, M-M-RVAXPRO

** MOPAVAC

*** MOVIVAC

* TRIMOVAX, PRIORIX, M-M-RVAXPRO

** MOPAVAC

*** MOVIVAC

* TRIMOVAX, PRIORIX, M-M-RVAXPRO

** MOPAVAC

*** MOVIVAC

* TRIMOVAX, PRIORIX, M-M-RVAXPRO

** MOPAVAC

*** MOVIVAC

Table 2

The antibodies against measles, mumps and rubella by age group in the measles outbreak, May–October 2018, the Michalovce and Sobrance districts in the Košice region, Slovakia (n=102).

Characteristic	0	1-4	5-9	10-14	15-19	20-24	25-34
All cases	23	45	12	13	7	2	102
	MEASLES
IgM n=68	13 (12.7)	31 (30.4)	8 (7.8)	11 (10.8)	4 (3.9)	1 (1.0)	68 (66.7)
IgG n=23	1 (1.0)	7 (6.9)	3 (2.9)	4 (3.9)	6 (5.9)	2 (2.0)	23 (22.5)
	MUMPS
IgG n=60	10 (9.8)	28 (27.5)	8 (7.8)	6 (5.9)	6 (5.9)	2 (2.0)	60 (58.8)
	RUBELLA
IgG n=20	2 (2.0)	3 (2.9)	3 (2.9)	4 (3.9)	6 (5.9)	2 (2.0)	20 (19.6)
	Positive antibodies against rubella and the type of applied combination vaccines (n=20) (%)
MMR+MMR	2 (10.0)	3 (15.0)	3 (15.0)	1 (5.0)	0	0	9 (45.0)
MM+MMR	0	0	0	3 (15.0)	1 (5.0)	0	4 (20.0)
Mo+Mo	0	0	0	0	5 (25.0)	2 (10.0)	7 (35.0)
TOTAL	2 (10.0)	3 (15.0)	3 (15.0)	4 (20.0)	6 (30.0)	2 (10.0)	20 (100.0)
	Negative antibodies against rubella and the type of applied combination vaccines (n=82) (%)
MMR+MMR*	21 (25.6)	42 (51.2)	9 (11.0)	9 (11.0)	0	0	81 (98.8)
MM+MMR**	0	0	0	0	0	0	0
Mo+Mo***	0	0	0	0	1 (1.2)	0	1 (1.2)
TOTAL	21 (25.6)	42 (51.2)	9 (11.0)	9 (11.0)	1 (1.2)	0	82 (100.0)

* MMR+MMR: two doses of trivalent vaccine against measles, mumps and rubella

** MM+MMR: one dose of bivalent measles-mumps vaccine, and one dose of trivalent measles-mumps-rubella vaccine

*** Mo+Mo: two doses of monovalent vaccine against measles

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/sjph-2020-0028 | Journal eISSN: 1854-2476 | Journal ISSN: 0351-0026

Journal RSS Feed

Language: English, Slovenian

Page range: 219 - 226

Submitted on: Feb 13, 2020

Accepted on: Sep 10, 2020

Published on: Oct 18, 2020

Published by: National Institute of Public Health, Slovenia

In partnership with: Paradigm Publishing Services

Keywords:

measles,

Related subjects:

Hygiene and environmental medicine

© 2020 Henrieta Hudečková, Janka Stašková, Ján Mikas, Adriana Mečochová, Edita Staroňová, Alexandra Polčičová, Tibor Baška, Martin Novák, Nora Malinovská, Jana Zibolenová, Viera Švihrová, Elena Nováková, Mária Štefkovičová, published by National Institute of Public Health, Slovenia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 59 (2020): Issue 4 (December 2020)

Measles outbreak in a Roma community in the Eastern region of Slovakia, May to October 2018

Figures & Tables

Figure 1

Figure 2

Figure 3

Table 1

Table 2

Paradigm

My account